AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call Transcript May 2, 2024 AtriCure, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to AtriCure’s First Quarter 2024 Earnings Conference Call. This call is being recorded for replay […]
AtriCure, Inc. (NASDAQ:ATRC) Q4 2023 Earnings Call Transcript February 15, 2024 AtriCure, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.22. AtriCure, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to AtriCure’s Fourth […]
MASON, Ohio, January 25, 2024 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024.